Melasma Game Changer

The presentation discusses the potential of tranexamic acid as a groundbreaking oral treatment for melasma, a skin condition affecting quality of life. Traditional melasma treatments often focus on topical applications like peels and lasers, but tranexamic acid, an FDA-approved medication for menorrhagia, shows promise due to its popularity in Asia and ease of use. The drug acts as a plasmid inhibitor to reduce UV-induced melanogenesis. Despite concerns regarding thrombosis risks, studies indicate no significant increase in thrombosis for users. A randomized placebo-controlled trial demonstrated a 49% improvement in melasma symptoms among patients taking tranexamic acid versus an 18% improvement in the placebo group. The drug was particularly effective in severe cases, with some sustained effects observed after treatment cessation. Although gastrointestinal discomfort and hypomenorrhea were common side effects, no thromboembolic events were reported, affirming its safety profile compared to other treatments like oral contraceptives. The conclusion emphasizes tranexamic acid's role as a game changer in melasma management, suggesting it as an adjunct to topical products for enhanced results.